Real-world outcomes of patients with papillary renal cell carcinoma treated with sunitinib and sorafenib: a non-interventional study

Jingyi Lu; Yizhe Zhang; Ruifan Zeng; Qihuang Lu; Ruiting Zhou

doi:10.47297/wspbdsWSP2752-630502.20220201

PDF
Export
Share
Collection
Album

Real-world outcomes of patients with papillary renal cell carcinoma treated with sunitinib and sorafenib: a non-interventional study

Volume 2, Issue 1

Views: 0 Downloads: 0

Real-world outcomes of patients with papillary renal cell carcinoma treated with sunitinib and sorafenib: a non-interventional study
Real-world outcomes of patients with papillary renal cell carcinoma treated with sunitinib and sorafenib: a non-interventional study
1.Harbin Medical University,Harbin Heilongjiang,150000,P.R.China
2.Shenzhen University,Shenzhen Guangdong, 518000,P.R.China
Vol. 2, Issue 1, Pages: 6-13(2022)
Published： 30 March 2022 ，
DOI：10.47297/wspbdsWSP2752-630502.20220201
Accepted：

Scan QR Code

Lu Jingyi,Zhang Yizhe,Zeng Ruifan,et al.Real-world outcomes of patients with papillary renal cell carcinoma treated with sunitinib and sorafenib: a non-interventional study[J].Biomedical Data Science,2022,02(01):6-13.
DOI：

Lu Jingyi,Zhang Yizhe,Zeng Ruifan,et al.Real-world outcomes of patients with papillary renal cell carcinoma treated with sunitinib and sorafenib: a non-interventional study[J].Biomedical Data Science,2022,02(01):6-13. DOI： 10.47297/wspbdsWSP2752-630502.20220201.

摘要

Abstract

Background

Papillary renal cell carcinoma (PRCC) is a special type of renal cell carcinoma

which is clinically different from other types of renal cell carcinoma

and how to choose the appropriate treatment for patients has become a problem for clinicians.

Objective

To assess the true outcomes of patients with papillary renal cell carcinoma treated with sunitinib and sorafenib.

Methods

We reviewed the clinical information of patients with papillary renal cell carcinoma treated with sunitinib and sorafenib at multiple oncology centers in China. 22 patients with papillary renal cell carcinoma were treated with sunitinib and 8 patients with papillary renal cell carcinoma were treated with sorafenib. All patients were followed up with clinical information for a mean period of 60 months

and follow-up data were recorded. The clinical information of the above patients was analyzed and survival was assessed using the Kaplan-Meier method

as well as univariate and multifactorial analyses by COX regression models.

Results

The DCR in the sunitinib and sorafenib groups were 45.45% and 50.00%

respectively

with no statistically significant difference between the two groups (P=0.53). During follow-up

the median overall survival (OS) was 24.00 months (95% CI: 7.47-40.53 months) and the mean overall survival (OS) was 59.36 months (95% CI: 32.43-86.30 months) in the sunitinib group; the median overall survival (OS) was 13.00 months (95% CI: 9.08-16.92 months) and the mean overall survival (OS) in the sorafenib group The median overall survival (OS) in the sorafenib group was 13.00 months (95% CI: 9.08-16.92 months)

and the mean overall survival (OS) was 21.44 months (95% CI: 8.91-33.98 months). The survival curve results showed that the area of the curve for patients with papillary renal cell carcinoma treated with sunitinib was larger than that for patients treated with sorafenib. COX regression models showed that age

gender

history of smoking

history of alcohol consumption

and history of surgery were not independent factors affecting the prognosis of patients with papillary renal cell carcinoma.

Conclusions

The difference in DCR between patients with papillary renal cell carcinoma treated with sunitinib and sorafenib was not statistically significant

but the area of the survival curve was large in patients treated with sunitinib. No independent factors affecting the prognosis of patients with papillary renal cell carcinoma were clearly derived.

关键词

Keywords

Papillary renal cell carcinomaSunitinibSorafenibSurvival analysisThe real ending

references

Purdue M P, Moore L E, Merino M J, et al. An investigation of risk factors for renal cell carcinoma by histologic subtype in two case-control studies[J]. Int J Cancer, 2013, 132(11): 2640-7.

Kavroulakis N, Ntougias S, Zervakis G I, et al. Role of ethylene in the protection of tomato plants against soil-borne fungal pathogens conferred by an endophytic Fusarium solani strain[J]. J Exp Bot, 2007, 58(14): 3853-64.

Ljungberg B, Campbell S C, Choi H Y, et al. Corrigendum to "The Epidemiology of Renal Cell Carcinoma" [Eur Urol 2011;60:615-21][J]. Eur Urol, 2011, 60(6): 1317.

Klatte T, Pantuck A J, Said J W, et al. Cytogenetic and molecular tumor profiling for type 1 and type 2 papillary renal cell carcinoma[J]. Clin Cancer Res, 2009, 15(4): 1162-9.

Escudier B, Eisen T, Stadler W M, et al. Sorafenib in advanced clear-cell renal-cell carcinoma[J]. N Engl J Med, 2007, 356(2): 125-34.

Cohen H T, Mcgovern F J. Renal-cell carcinoma[J]. N Engl J Med, 2005, 353(23): 2477-90.

Rini B I, Campbell S C, Escudier B. Renal cell carcinoma[J]. Lancet, 2009, 373(9669): 1119-32.

Chowdhury S, Choueiri T K. Recent advances in the systemic treatment of metastatic papillary renal cancer[J]. Expert Rev Anticancer Ther, 2009, 9(3): 373-9.

Checkpoint Inhibitor-TKI Combos Effective in RCC[J]. Cancer Discov, 2019, 9(4): 460.

Sharma R, Kadife E, Myers M, et al. Determinants of resistance to VEGF-TKI and immune checkpoint inhibitors in metastatic renal cell carcinoma[J]. J Exp Clin Cancer Res, 2021, 40(1): 186.

Jacobsen J, Grankvist K, Rasmuson T, et al. Expression of vascular endothelial growth factor protein in human renal cell carcinoma[J]. BJU Int, 2004, 93(3): 297-302.

Motzer R J, Jonasch E, Boyle S, et al. NCCN Guidelines Insights: Kidney Cancer, Version 1.2021[J]. J Natl Compr Canc Netw, 2020, 18(9): 1160-1170.

Armstrong A J, Halabi S, Eisen T, et al. Everolimus versus sunitinib for patients with metastatic non-clear cell renal cell carcinoma (ASPEN): a multicentre, open-label, randomised phase 2 trial[J]. Lancet Oncol, 2016, 17(3): 378-388.

Tannir N M, Jonasch E, Albiges L, et al. Everolimus Versus Sunitinib Prospective Evaluation in Metastatic Non-Clear Cell Renal Cell Carcinoma (ESPN): A Randomized Multicenter Phase 2 Trial[J]. Eur Urol, 2016, 69(5): 866-74.

Hong Baoan, Hou Huimin, Chen Lingxiao, et al. Clinicopathological characteristics and prognosis of papillary renal cell carcinoma Clinicopathological features and prognostic analysis of papillary renal cell carcinoma [J]. Chinese Journal of Urology, 2020, 41( 12) : 896 - 900.

Hong B，Hou H，Chen L，et al． The clinicopathological features and prognosis in patients with papillary renal cell carcinoma: A multicenter retrospective study in Chinese population ［J］． Front Oncol，2021，11: 753690．

Ha YS，Chung JW，Choi SH，et al． Clinical significance of subclassification of papillary renal cell carcinoma: Comparison of clinicopathologic parameters and oncologic outcomes between papillary histologic subtypes 1 and 2 using the Korean renal cell carcinoma database［J］． Clin Genitourin Cancer，2017，15( 2) : e181 － e186．

Sukov WＲ，Lohse CM，Leibovich BC，et al． Clinical and pathological features associated with prognosis in patients with papillary renal cell carcinoma ［J］． J Urol，2012，187( 1) : 54 － 59．

Delahunt B, Eble J N, Mccredie M R, et al. Morphologic typing of papillary renal cell carcinoma: comparison of growth kinetics and patient survival in 66 cases[J]. Hum Pathol, 2001, 32(6): 590-5.

Alert me when the article has been cited

Submit

No data

Related Author

No data

Related Institution

No data

⁰